Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 8,600 shares, a decrease of 86.8% from the January 15th total of 65,100 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ? days.

Antibe Therapeutics Stock Performance

ATBPF remained flat at $0.22 during trading on Friday. The firm’s fifty day simple moving average is $0.22 and its two-hundred day simple moving average is $0.22. Antibe Therapeutics has a fifty-two week low of $0.11 and a fifty-two week high of $0.89. The firm has a market cap of $11.42 million, a PE ratio of -0.86 and a beta of 0.51.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).